Raymond James lowered the firm’s price target on Aquestive Therapeutics (AQST) to $7 from $8 and keeps an Outperform rating on the shares. Aquestive’s Q4 results slightly missed expectations, but the focus remains Anaphylm progress on track to be filed soon, and Aquestive is preparing for launch in the first quarter of 2026, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AQST:
- Aquestive Therapeutics price target lowered to $8 from $10 at Lake Street
- Aquestive Therapeutics price target lowered to $4.75 from $5.50 at Alliance Global Partners
- Aquestive Therapeutics Reports 2024 Financial Results and Strategic Progress
- Aquestive Therapeutics: Strategic Advancements and Financial Strength Underpin Buy Rating
- Aquestive Therapeutics Initiates Anaphylm NDA Filing Process